NEWS | SAN DIEGO

Lpath to begin trading on Nasdaq Capital Market

By

San Diego-based Lpath Inc., which develops bioactive lipid-targeted therapeutics, received confirmation that its application to list the company's common stock on the Nasdaq Capital Market has been approved by the Nasdaq Stock Market, a unit of the Nasdaq OMX Group.

TO CONTINUE READING, SUBSCRIBE NOW
OR
LOG IN TO YOUR ACCOUNT
User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Lpath Inc.

Company Website

6335 Ferris Sq. Ste., A
San Diego, CA 92121
Map It

Lpath Inc. Executive(s):

Scott Pancoast

  • Chief Executive Officer, President

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
SIC - 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES



Subscribe Today!

contact info: Iam Pam